Kornimate/medical-research-clean huggingface dataset:
predicting outcome in cervix carcinoma: a prospective study

Conditions: Cervical Cancer

Summary: the main aim is to validate and improve the predictive model for survival and toxicity in patients with cervical cancer through multicentric prospective data collection. the data contain information on patient, tumor and treatment characteristics. for this study, additional health related qol scores will be assessed using the eortc quality of life questionair-cx24 and c30. the long term aim, beyond this specific study, is to build a decision support system based on the predictive model validated in this study.


Eligibility criteria:
inclusion criteria: * histological or cytological proven cervical cancer * informed consent according to national rules exclusion criteria: * no histological or cytological proven cervical cancer * no informed consent according to national rules

Keywords: cervical cancer
a 3 years naturalistic cohort survey of altis single incision sling system for female stress urinary incontinence

Conditions: Urinary Incontinence, Stress

Summary: the purpose of this study is to monitor the use of altis single incision sling (sis) in a real world population and collect medical data on effectiveness and to monitor safety of altis sis at 12 and 36 months post device implantation in women with stress urinary incontinence.

this project has been launched after the introduction of altis in europe. this study is a multicenter prospective, observational (i.e. naturalistic) post-marketing clinical follow-up of women for who stress urinary incontinence was diagnosed and will be treated with altis single incision sling system. therefore these patients will be asked to allow to use their clinical data and answer some questionnaires. the patients'data will be collected in routine clinical practice before, during and after surgery until 12 months. then, questionnaires will be mailed to the participants annually during 2 additional years.

Eligibility criteria:
inclusion criteria: * implanted with altis single incision sling system exclusion criteria: * refuses to be included in the survey or that their medical data will be used for research purposes * indication for altis single incision sling system implantation is not for the treatment of female urinary incontinence.

Keywords: single incision sling
utilization of target ranges to treat parkinson's disease with the pkg

Conditions: Parkinson Disease

Summary: the main objective of this study is to evaluate whether people whose pd symptoms are uncontrolled who are managed with the aid of objective measurement and use of target ranges have improved pd symptoms and outcomes as compared to individuals treated using only standard of care (medical history, neurological examination).

this is a randomized controlled trial (rct) to evaluate treating uncontrolled patients with parkinson's disease (pwp) to a target range as suggested by expert review papers. the study aims to evaluate clinical patient outcomes, quality of life measures and health care utilization of those patients specifically treated to a target range when using the pkg data in the clinical management of parkinson's disease (pd) in routine clinical care (treatment group) compared to those managed with medical history and clinical evaluation alone (control group) performed by a neurologist experienced in pd management. both groups will be recommended to undergo medication changes until they reach a "controlled state" that is determined by either the clinician using standard of care (soc) (pkg- group) or using pkg based targets and soc assessments (pkg+ group).

Eligibility criteria:
inclusion criteria: * able and willing to sign a written informed consent for study participation * presumed to have levodopa responsive idiopathic parkinson's disease * age inclusive at the time of consent per pkg indications for use (46-83 years old) * has not been previously managed with the pkg exclusion criteria: * contraindication to increasing levodopa (e.g. orthostatic hypotension, hallucinations/psychosis or any other medical condition in the last year that would preclude increasing levodopa or other appropriate parkinson's disease medications) * moca score \<23 at screening visit * diagnosis of essential tremor * wheelchair bound or bedridden * currently utilizing or planning in the next 6 months advanced pd therapies (dbs, infusion, etc.) * in the investigator's or sponsor's opinion, subject has any unstable or clinically significant condition that would impair the participant's ability to comply with study requirements or interfere with interpretation of the study endpoints (e.g., subject unable to complete pkg watch wear instructions per patient instruction manual)

Keywords: personal kinetigraph (pkg) movement recording system objective measurement
effectiveness of a customized 3d printed nostril retainer combined with taping vs.taping only on enhancing the nasolabial esthetics and maxillary arch dimensions in infants with unilateral complete cleft lip and palate.

Conditions: Cleft Lip and Palate

Summary: lip taping was proven as simple, handy technique of psio for alveolar molding yielding enhanced maxillary arch dimensions in ucclp infants. the approach behind this study is to combine this simple step with a digitally designed 3d printed customized nasal molding device to enhance the naslolabial esthetics and maxillary arch dimensions in infants with unilateral complete cleft lip and palate, employing full digital workflow.


Eligibility criteria:
inclusion criteria: 1. infants with age range from 1-30 days. 2. unilateral complete cleft lip and palate 3. medically free subjects. 4. both males and females. exclusion criteria: 1. patients older than 30 days. 2. syndromic patients with other defects in addition to cleft lip and palate. 3. patients with bilateral cleft lip and palate. 4. incomplete cleft lip. 5. patient with previous surgical lip repair or adhesion. 6. patients with previous presurgical infant orthopedic treatment. 7. medically compromised patients.
french national registry of adults with growth hormone deficiency treated with somatropin

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this study is conducted in europe. the aim of this study is to extract data from the french national registry holding information about patients having initiated growth hormone therapy with the objective to describe patients receiving growth hormone therapy, assess efficacy and safety of somatropin (norditropin® simplexx®) and evaluate treatment compliance.


Eligibility criteria:
inclusion criteria: * adult with growth hormone deficiency * treated with norditropin® simplexx (somatropin)
measurement of circulating tumor cells in prostate cancer

Conditions: Prostatic Neoplasms

Summary: can tumor cells and tumor dna be sampled from blood samples from prostate cancer patients? is it possible to understand the causal relationship between the occurrence of the tumor cells and the tumor dna in the blood by reviewing the patient's medical records, including information about investigations, analytical reports or diagnoses? can gene defects that may be useful in predicting the best treatment be detected by sequencing individual tumor cells or plasma from blood samples?

prostate cancer is the most common form of cancer in men and the second most deadly. today's diagnostic methods and treatments are therefore obviously not adequate. in this study we will evaluate a new diagnostic sampling and analysis method for prostate cancer, not try new treatments. the test sampling involves the rare tumor cells and tumor dna found in the blood, and sequencing their dna to determine which, if any, defective genes they contain that may explain the disease. there is currently no universally accepted diagnostic test of either tumor cells or tumor dna in blood. we have access to new technology that one of us (ce) developed at the karolinska institute, which by all accounts can give access to the rare tumor cells in the blood so that we can sequence their dna. in this study we want to try to see if it is possible in practical healthcare to apply the new technology for prostate cancer patients and if there are signs that it works equally well in the healthcare environment as in the laboratory. impact: if the sampling of tumor cells and tumor dna from blood samples works within the healthcare system processes, it will be possible to understand the causal relationships behind their occurrence, and their gene defects, we can design follow-up studies that would take us closer to clinical use of the new technology to predict which treatment would be most effective and which treatment would produce the least side effects. ethical considerations: the risks of blood sampling are limited and known and can be managed within the healthcare system. data is handled safely. the potential future benefit of a new cancer cell- and dna-test is great. the study is a collaboration between region sörmland, karolinska institutet and icellate medical ab. the data collection is expected to be completed in 2020 and the analyses in 2021.

Eligibility criteria:
inclusion criteria: * patients diagnosed with prostate cancer of moderate risk planned for prostatectomy with lymph node removal, or * patients diagnosed with prostate cancer stage 3, or * patients with diagnosed prostate cancer stage 4, or * patients with diagnosed benign inflammatory prostatitis or other benign urological condition constituting age-matched, cancer free, controls exclusion criteria: * patients undergoing prostate cancer treatment (no prostate cancer treatment should be given to the patient before blood collection) * patients with previous malignancy

Keywords: prostate cancer, biomarker
rifaximin prophylaxis for spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhotic patients

Conditions: Ascites Infection

Summary: norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial peritonitis (sbp) in patients with liver cirrhosis. rifaximin, another broad spectrum antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's diarrhea and prevention of hepatic encephalopathy.

prophylaxis against spontaneous bacterial peritonitis (sbp) in cirrhotic patients recovered from an episode of sbp using norfloxacin 400 mg/day is currently established standard of care. recently we are facing the growing challenge of standard sbp prophylaxis lacking efficacy as extended spectrum beta-lactamases and fluoro-quinolone resistant bacteria in isolates of patients on norfloxacin. prophylaxis against hepatorenal syndrome in decompensated liver cirrhosis is limited to iv administration of albumin in patients who develop sbp and the prevention of sbp using norfloxacin. this study aims to investigate the effectiveness of rifaximin in decompensated cirrhotic patients against sbp as a secondary prophylaxis measure and hepatorenal syndrome. our study was non inferiority prospective non randomized controlled trial the study enrolled patients with chronic liver disease and ascites who were monitored at outpatient clinics or who were admitted to ain shams university hospitals.104 patients with decompensated liver cirrhosis were enrolled in the study, the control group (n=52), to receive standard of care treatment \& norfloxacin prophylaxis for the decompensated liver disease and a second treatment group (n=52) who will receive rifaximin prophylaxis in addition to the original management.

Eligibility criteria:
inclusion criteria: 1. decompensated cirrhotic patients (child b or c, ascetic patients). 2. adult male/female aged \>18 years old. 3. history or evidence of previous attack of sbp and currently clinically free from sbp. exclusion criteria: 1. recent abdominal surgery. 2. patients with renal impairment (serum creatinine \>1.5mg/dl) at baseline. 3. patients on renal replacement therapy (rrt) at baseline. 4. sonographic evidence of nephropathy other than grade i nephropathy in ascetic patients 5. intraabdominal source of infection (e.g. intra-abdominal abscesses, cholecystitis or acute pancreatitis). 6. patients with current evidence of upper urinary tract infection. 7. other comorbidities affecting the patient survival e.g. significant cardiac disease, pulmonary disease, portal vein thrombosis, hepatocellular carcinoma or other malignancies, etc. 8. sepsis. 9. current or recent treatment with nephrotoxic drugs or contrast material injection.

Keywords: rifaximin norflixacin spontaneous bacterial peritonitis
the use of armeo spring in upper extremity rehabilitation

Conditions: Hemiplegia; Cerebral Palsy; Upper Extremity Weakness

Summary: the purpose of this study is to evaluate the use of the armeo®spring pediatric as therapy for children with hand and arm weakness. the armeo®spring pediatric is a device that supports the weight of the child's arm and uses joystick that helps to play computer games. the child will be assessed before and after this therapy. participating children with upper extremity impairments will receive therapy 3x/week for 6 weeks during 30-45 minutes sessions at progressively increasing degrees of difficulty. each child's performance will be tracked with regard to time necessary to complete a predetermined number of trials of the activity. the standardized assessment tools that will be used are the assisting hand assessment (aha), box \& blocks test, jebsen taylor hand function test, and the pediatric evaluation of disability inventory-computer adaptive test (pedi-cat). data will be analyzed to determine the efficacy of this training method.

8. "adverse events" all serious adverse events will be reported to the irb immediately, but no later than \[5\] days of the occurrence or receipt of notification from an outside source; the irb can make changes to the consent form as a result of adverse events. any such event will be reported to the irb on the "adverse event report." \[see attachment.\] 9. "debriefing" debriefing is not required because there is no deception of subjects involved or there are no alternative treatments or procedures used in a "blind" fashion. 10. "intervention" participants in this study are children who present with a diagnosis of upper extremity weakness or involvement secondary to various reasons. these children receive occupational, physical, and/or speech services at st mary's hospital for children. the children participating in this program will be receiving their occupational therapy session with the use of the armeo®spring pediatric. they will also continue to receive their regular physical and speech therapy session. once the program is completed, they will continue to receive their regular occupation therapy sessions. 11. "confidentiality" data sheets will be coded with a number to represent each child. the numeric data obtained regarding timed trials will be entered into a computer which is password-protected at st. mary's hospital for children in bayside, ny. consent forms with the child's name and parental signatures and video tape or photographic images recorded during data collection will be stored in accordance with st. mary's hospital for children patient privacy policy.

Eligibility criteria:
inclusion criteria: * age between 7 -17 years. * arm weakness secondary to various causes. * armeo®spring pediatric fit * upper arm measures:155mm-235mm (7 to 9.5 inches) * lower arm measures: 230mm-370mm (9inches to 14 inches) * ability to follow instructions. exclusion criteria: * vision deficits * contractures that do not allow use of system. * spasticity that does not allow use of system. * osteopenia * recent surgeries to the involved upper extremity.
smad2, smad3 and tgf-β gene expression in urge urinary incontinence

Conditions: SMAD2; SMAD3; TGF-β; Pelvic Organ Prolapse; Urge Urinary Incontinence

Summary: urge urinary incontinence (uui) is a common health problem. changes in collagen metabolism in pelvic support organs, such as uterosacral ligaments (usls), might be responsible for the complex pathophysiology of uui. the tgf-β pathway is involved in collagen synthesis and degradation. the transforming growth family- β (tgf-β) superfamily has essential intracellular signaling components, such as newly identified smad family members. we evaluated the changes in the levels of tgf-β and smad gene and protein expression in the usl of patients with concomitant pelvic organ prolapse (pop) and uui.

this study included 10 patients who had been diagnosed with pop and uui in the study group and 14 asymptomatic women without complaints of pop and uui in the control group. biopsy samples were collected from bilateral usl tissues during vaginal or abdominal hysterectomy. total rna was extracted from usl tissue and analyzed by qpcr. the protein expression levels were also analyzed with elisa.

Eligibility criteria:
inclusion criteria: * patients who had been diagnosed with pop and uui * asymptomatic women without complaints of pop and uui exclusion criteria: * women who have sui, * a history of gynecologic malignancy, * endometriosis, * connective tissue disorders, * asthma, * previous pelvic inflammatory disease, * pelvic radiation anamnesis, * smoking, * previous surgery for pop or ui, * those on steroid therapy and hormone replacement therapy
nutrition education for cardiovascular disease prevention in spinal cord injury

Conditions: Spinal Cord Injury

Summary: this is a randomized controlled trial to study a nutrition education intervention in individuals with spinal cord injuries both in the acute rehabilitation setting (n = 100) and the community setting (n = 100). participants in the treatment group will receive six interactive nutrition lectures based upon a successful program that has been used in older adults titled "eat smart, stay well". the goals of intervention are to improve whole-grain, fruit and vegetable, and low-fat dairy intake and reduce fat and saturated fat intake. secondary outcomes will include improvements in waist circumference of body mass index and some biomarkers such as cholesterol and blood sugar.

the prevalence of sci is significant. obesity, diabetes, and cvd are more prevalent in the sci population. many individuals with sci are unable or have a limited capacity to exercise. this reality makes good nutrition even more urgent. this study will be the first to test whether additional nutrition education can improve nutrition behavior and knowledge, diet quality, adiposity, and metabolic cvd risk factors in individuals with sci and to determine the best setting to deliver nutrition education to individuals with sci.

Eligibility criteria:
inclusion criteria: * american spinal injury association classification a, b, c as long as they are not functional ambulators exclusion criteria: * stage iii or iv pressure ulcers, pregnancy, end-stage renal disease, treatment for cancer except for nonmelanoma skin cancer within the past five years, and chronic, nontobacco substance-abuse, cognitive impairment with inability to learn
the second covid-19 wave: collateral impact on patients of liver disease

Conditions: Liver Diseases

Summary: hospital record of the patients of liver disease admitted from april-may 2021 and april-may 2019 will be reviewed. patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and the subsequent 30 d and 90 day readmission rate. monitoring and assessment: hospital records of all patients of liver disease needing admission during the april-may 2019 and 2021, but without active covid-19 infection, will be reviewed. patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and 30 d and 90 d readmission rate.


Eligibility criteria:
inclusion criteria: 1. patients of liver disease requiring hospital admission exclusion criteria: 1. active covid-19 infection at time of admission or acquiring during hospital stay.
effectiveness of maternal immunization with boostrix at preventing pertussis among infants <2 months old in the united states

Conditions: Whooping Cough

Summary: the purpose of this study is to estimate the effectiveness of maternal immunization with boostrix at preventing pertussis in infants in the united states.


Eligibility criteria:
inclusion criteria: inclusion criteria for case infants: * case infants were eligible for the enrolment if they: * were at least 2 days old and \< 2 months old on the cough onset date * resided in the catchment area on their cough onset date * were born in a hospital in their state of residence * were ≥37 weeks' gestational age at birth * were neither adopted nor in foster care * did not live in a residential care facility inclusion criteria for control infants: * control infants were eligible for the enrolment if they: * were at least 2 days old and \<2 months old on the case infant's cough onset date * were born in a hospital in their state of residence * were ≥37 weeks' gestational age at birth * were neither adopted nor in foster care * did not live in a residential care facility * were born at the same hospital as the case infant did not have pertussis diagnosis prior to the cough onset date of the corresponding case infant exclusion criteria: * infants (case and controls) whose mothers have received adacel or mothers without brand information available, as well as controls who were matched to a case whose mother received adacel or mothers without brand information available, will be excluded from the analysis of the effectiveness of vaccination with boostrix.

Keywords: whooping cough boostrix tdap effectiveness pregnancy infants